Celgene and Quanticel Pharmaceuticals announced a definitive share purchase agreement under which Celgene will acquire Quanticel.
Through the agreement, Celgene will have full access to Quanticel’s proprietary platform for the single-cell genomic analysis of human cancer, as well as Quanticel’s lead programs that target specific epigenetic modifiers to advance Celgene’s pipeline of innovative cancer therapies.
|Searching for more deal information? Current Partnering offers the following options:
The acquisition culminates a 2011 strategic alliance between Celgene and Quanticel.
Over the course of the three-and-a-half year alliance, Quanticel industrialized its single-cell platform for analysis of tumor cellular content and applied it to novel target discovery and the generation of high-quality drug candidates.
Multiple drug candidates from Quanticel are expected to enter the clinic in early 2016.
Celgene will acquire Quanticel for an upfront payment of $100 million in cash.
Up to an additional $385 million in contingent payments may be achieved upon research, development, and regulatory advances related to Quanticel’s research and development platform.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top biotech companies